Paul Sturman Net Worth

Paul Sturman biography

Paul L. Sturman serves as Independent Director of the Company. He has been a member of our Board since March 2017. Mr. Sturman has worked in the healthcare industry in a variety of leadership positions. Mr. Sturman worked at Pfizer from January 2009 to September 2014 where he ran the Global Consumer Healthcare division, one of the largest over-the-counter healthcare products companies in the world. He also previously served at Johnson & Johnson from January 2007 to December 2008 as President of its North American Consumer Health division as well as numerous leadership roles in marketing, brand, and sales management with Warner Lambert. Since September of 2017, Mr. Sturman has served as Chief Executive Officer of Nature’s Bounty Co., a nutritional science products company. Mr. Sturman also briefly served as President and CEO of NJOY, Inc. (“NJOY”) from January 2015 to July 2016. On September 16, 2016, NJOY filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in U.S. Bankruptcy Court in Delaware. He was a member of the Board of Trustees of the Foundation for Morristown Medical Center from December 2012 to December 2017, which works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine.

What is the salary of Paul Sturman?

As the Independent Director of Tyme Technologies Inc, the total compensation of Paul Sturman at Tyme Technologies Inc is $90,884. There are 12 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.

How old is Paul Sturman?

Paul Sturman is 59, he's been the Independent Director of Tyme Technologies Inc since 2017. There are 7 older and 10 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.

What's Paul Sturman's mailing address?

Paul's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.

Insiders trading at Tyme Technologies Inc

Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian és Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.

What does Tyme Technologies Inc do?

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.

With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Tyme Technologies Inc executives and stock owners

Tyme Technologies Inc executives and other stock owners filed with the SEC include:

• James Biehl,
  Chief Legal Officer and Corporate Secretary
• Michele Korfin,
  Chief Operating Officer
• Steve Hoffman,
  Chairman of the Board, Chief Executive Officer, Chief Science Officer
• Steven E. Hoffman,
  Co-Founder, Chairman & Chief Science Officer
• James Biehl J.D.,
  Chief Legal Officer & Sec.
• Dr. Jonathan M. Eckard,
  Chief Bus. Officer
• Richard Cunningham,
  CEO & Director
• David Carberry,
  Independent Director
• Donald Degolyer,
  Independent Director
• Gerald Sokol,
  Independent Director
• Timothy Tyson,
  Independent Director
• Douglas Michels,
  Independent Director
• Paul Sturman,
  Independent Director
• Jonathan Eckard,
  Chief Business Officer
• Giuseppe Del Priore,
  Chief Medical Officer
• Barbara Galaini,
  Principal Financial Officer, Principal Accounting Officer, Corporate Controller
• Frank L. Porfido,
  Chief Financial Officer
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
  Acting Chief Medical Officer
• Dr. John M. Rothman,
  Exec. VP of Product Devel.
• John Zucaro P.E.,
  Sr. VP of CMC
• Tommy G Thompson,
  Director
• Christine D. Baker,
  Director
• John M. Rothman,
  EVP, Product Development
• Michael Demurjian,
  10% owner
• Ben R Taylor,
  President, CFO
• Tornout Jan M Van,
  Acting Chief Medical Officer
• Christopher F Brown,
  10% owner
• Frank L. Porfido,
  Chief Financial Officer
• Richard Anthony Cunningham,,
  Chief Executive Officer